UK Union to Fight Closure of Sanofi UK Manufacturing Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

UK Union to Fight Closure of Sanofi UK Manufacturing Facility


ePT--the Electronic Newsletter of Pharmaceutical Technology

Unite, Britain and Ireland’s largest trade union with 1.5 million members, said it will fight the closure of Sanofi’s pharmaceutical manufacturing facility in Newcastle-upon-Tyne in northeast England. Last week, Sanofi announced the closure of the facility, which employs 450 people and makes solid dose oral drugs mainly for the UK and European markets.

“The way the workforce and the union were advised this site is to close is completely unacceptable,” said Unite National Officer Linda McCulloch in a Mar. 15, 2012, Unite statement. “There was no prior warning and no consultation. This would never have been allowed to happen in other EU countries such as France or Germany. The company would have been expected to work with the union to explore ways to keep the site open.”

Sanofi plans to close the Fawdon manufacturing center in Newcastle-upon-Tyne by mid-2015. The company cited adverse economic conditions, including generic-drug competition, which has contributed to a fall in demand and production volumes at the facility.

“Employees at the site have been notified of the proposal (Mar. 14th) and a process of collective consultation with employee representatives is now underway,” said Sanofi in a prepared statement. “We will support our people in every way we can to best manage the impact of this announcement and to help them through the consultation process and beyond.”

“Unite is going to fight this closure,” said McCulloch in the statement. “This company has benefited from the commitment of the local community for decades. We now expect the company to sit down with the union to explore every avenue possible to keep manufacturing at this site. The workforce at the company deserves better than being told at a moment’s notice that the site is to close and then being sent home. ‘We are appalled at the way this has been handled—there has been scant regard for the hard working and skilled workforce.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here